In this study, we found that PAFR antagonist rupatadine, which is a clinical used PAFR and H1 receptor dual inhibitor, suppresses CSE induced autophagic cell death, decreases the release of elastase from neutrophils, protects mice from CS caused COPD. This evidence concerns the gene PTAFR and Cowden syndrome 1.